7CU5 image
Entry Detail
PDB ID:
7CU5
Keywords:
Title:
N-Glycosylation of PD-1 and glycosylation dependent binding of PD-1 specific monoclonal antibody camrelizumab
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2020-08-21
Release Date:
2020-10-14
Method Details:
Experimental Method:
Resolution:
2.81 Å
R-Value Free:
0.25
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:camrelizumab-scFv
Chain IDs:A (auth: B), C (auth: A)
Chain Length:230
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Programmed cell death protein 1
Chain IDs:B (auth: E), D (auth: Q)
Chain Length:118
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
N-glycosylation of PD-1 promotes binding of camrelizumab.
Embo Rep. 21 e51444 e51444 (2020)
PMID: 33063473 DOI: 10.15252/embr.202051444

Abstact

PD-1 is a highly glycosylated inhibitory receptor expressed mainly on T cells. Targeting of PD-1 with monoclonal antibodies (MAbs) to block the interaction with its ligand PD-L1 has been successful for the treatment of multiple tumors. However, polymorphisms at N-glycosylation sites of PD-1 exist in the human population that might affect antibody binding, and dysregulated glycosylation has been observed in the tumor microenvironment. Here, we demonstrate varied N-glycan composition in PD-1, and show that the binding affinity of camrelizumab, a recently approved PD-1-specific MAb, to non-glycosylated PD-1 proteins from E. coli is substantially decreased compared with glycosylated PD-1. The structure of the camrelizumab/PD-1 complex reveals that camrelizumab mainly utilizes its heavy chain to bind to PD-1, while the light chain sterically inhibits the binding of PD-L1 to PD-1. Glycosylation of asparagine 58 (N58) promotes the interaction with camrelizumab, while the efficiency of camrelizumab to inhibit the binding of PD-L1 is substantially reduced for glycosylation-deficient PD-1. These results increase our understanding of how glycosylation affects the activity of PD-1-specific MAbs during immune checkpoint therapy.

Legend

Protein

Chemical

Disease

Primary Citation of related structures